Improving the efficacy of cancer immunotherapy-Reference-Cited by-同舟云学术

Improving the efficacy of cancer immunotherapy

Published:2009-05 Issue:8 Volume:45 Page:1424-1431
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Copier J.,Dalgleish A.G.,Britten C.M.,Finke L.H.,Gaudernack G.,Gnjatic S.,Kallen K.,Kiessling R.,Schuessler-Lenz M.,Singh H.,Talmadge J.,Zwierzina H.,Håkansson L.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference44 articles.

1. Lessons from randomized phase III studies with active cancer immunotherapies – outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC);Finke;Vaccine,2007

2. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas;McCarthy;Iowa Orthop J,2006

3. Understanding intravesical BCG: a window to the future treatment of noninvasive bladder cancer;Loughlin;Urol Oncol,2008

4. A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy;Assersohn;Clin Oncol (R Coll Radiol),2002

5. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results;O’Brien;Ann Oncol,2004

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spatial profiling of ovarian clear cell carcinoma reveals immune-hot features;2023-07-29

2. Regulatory landscape in the approval of cancer vaccine;Nanotherapeutics in Cancer Vaccination and Challenges;2022

3. The Diversification of Cell Death and Immunity: Memento Mori;Molecular Cell;2019-10

4. Repurposing Food and Drug Administration–Approved Drugs to Promote Antitumor Immunity;The Cancer Journal;2019-03

5. HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation;Oncology Letters;2017-08-21